NCT00698984已完成不适用
Pilot Study To Investigate The Effect Of Bonistein(R) Bone Blend Containing Genistein, Polyunsaturated Fatty Acids (N-3 PUFAS) And Vitamins K1 And D3 On Bone Mineral Density (BMD), Bone Mineral Content (BMC) And Biomarkers Of Bone Health In Early Postmenopausal Women
DSM Nutritional Products, Inc.2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2007年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 2
- 主要终点
- Bone Mineral Density/Content (BMD/BMC) at lumbar spine and femoral neck
研究概览
简要总结
The purpose of this study is to obtain information about the effect of a combination of genistein, PUFAs, vitamin K and D (BONISTEIN(R) bone blend) on bone health, determined as bone mass density/content and bone biomarkers after 6-months treatment in 70 healthy postmenopausal women. In addition, safety and tolerability will be investigated.
详细描述
Osteoporosis is the most frequent disease of the skeletal system with approximately one third of all postmenopausal women being currently affected in the USA and in Europe. The role of nutrition in bone health has been increasingly recognized in the last couple of years. In particular nutrients such as isoflavones, vitamins D and K as well as polyunsaturated fatty acids (PUFA) have been implicate in bone health recently.
The DSM Nutritional Products Ltd product BONISTEIN(R) is a synthetic genistein. Its genistin aglycone purity is above 99 % and the appearance is a beige crystal.
In addition to the primary and secondary outcomes, body composition, genistein plasma levels, diet and physical activity are assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Age 45 (inclusive) to 55 years (inclusive)
- •Race: Caucasian
- •Non-smokers / Smokers up to 10 cigarettes/day
- •Postmenopausal hormone status: 1-3 years since the last spontaneous menstrual bleeding and a follicle-stimulating hormone concentration (FSH) >75 IU/ml and 17-estradiol (E2) of < 20 ng/L
- •Years since menopause between 1-3 years
- •Natural menopause or total hysterectomy with bilateral salpingo-oophorectomy
- •Subjects with E2 results within the inclusion criteria range will be assessed on an individual basis if FSH level is less than 75 IU/ml
- •Assessed as age-related healthy, based on a pre-study examination including medical history, physical examination, ECG, vital signs and clinical laboratory. The examination will be performed by a MD at the study site within 1-2 months prior planned study start for the individual subject.
- •Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements.
- •Ability to understand, speak, read and write the English language
排除标准
- •T-score < -2.5 at total hip and spine (either or both)
- •Suspect lack of compliance
- •BMI > 30 or < 21
- •Use of HRT within the previous 6 months
- •Use of any drug which might interfere with bone-metabolism (bisphosphate, estrogen receptor modulators, calcitonin) within the previous 12 months
- •Systematic practice of high intensity exercise
- •Vegetarian nutrition or any other extreme dietary habits
- •Use of dietary supplements while on study, except multi vitamin. No "wash out" period for supplements - must stop before run-in period and refrain until the end of the study.
- •Participant in any other study or donation of blood during the last 30 days before start of each dosing phase (T0).
- •Total genistein blood concentrations of > 100 ng/ml measured at pre-study examination
- •Known hypersensitivity or allergy to soy, purified isoflavones, peanuts, fish, and/or genistein.
- •Hepatitis screen (serology) positive or not performed
- •Drug screen positive or not performed (at least amphetamines, benzodiazepines, cannabinoides, opiates).
- •Subjects on a weight reduction program or a medically supervised diet
- •Unexplained weight loss or weight gain of more than 5 kg in the three months prior to the study
- •History of liver or pancreas diseases
- •Cardiovascular diseases, even AV-block I0 (PQ time > 220 ms) and QTc time > 450 ms
- •History of breast cancer, endometrial cancer and other malignancy except basal and squamous cell skin cancer
- •History of thromboembolism or deep venous thrombosis
- •Any fractures within one year except for fingers, toes and facial bones
- •Subjects with susceptibility for fractures as a history of being a faller
- •Endometrial thickness > 6 mm
- •Endometrial polyps
- •Untreated hypo- or hyperthyroidism
- •Insulin-dependent diabetes mellitus, Crohn's Disease, Cushing Disease etc.
- •Any condition which might interfere with absorption of the investigational product (e.g. malabsorption syndrome)
- •Co-medication: Anticoagulants, parathyroid hormones, corticosteroids, thiazide diuretic
- •Subjects who, during the previous 24 months, received a total fee payment greater than 5'000 USD for participation in biomedical research
结局指标
主要结局
Bone Mineral Density/Content (BMD/BMC) at lumbar spine and femoral neck
时间窗: Baseline and after 6 months
次要结局
- BMD/BMC on whole body, Ward's Triangle, total hip, and (inter)trochanter Bone resorption markers: DPD, NTX, RANKL/OPG Bone formation markers: bALP, OC, ucOC(Baseline and after 3 and 6 months (bone markers))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Natural Versus Synthetic Vitamin B Complexes in HumanHealthyThiamine and Niacin Deficiency StatesPyridoxine DeficiencyFolic Acid Deficiency Anemia, DietaryVitamin B 12 DeficiencyPolyphenolsOxidative StressMetabolic Disorder HomocystineDefect PeroxidaseNCT03444155Medical University of Graz30
终止
1 期
Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)Cystic FibrosisNCT00590538Children's Hospital of Philadelphia9
撤回
4 期
A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar DepressionBipolar DepressionBipolar DisorderNCT02719392Massachusetts General Hospital40
已完成
1 期
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple MyelomaMultiple MyelomaNCT01549431Emory University32
已完成
3 期
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)Non-Hodgkin's LymphomaMantle Cell LymphomaNCT01073163Cephalon54